David Durantel
  • E-mail :[email]
  • Phone : +33 4 72 68 19 59
  • Location : Lyon, France
Last update 2020-11-22 15:37:50.978

David Durantel Molecular and Cellular Virologist, PhD, HDR

Course and current status

I have obtained my PhD in Molecular and Cellular Virology at the University of Montpellier in 1997. After three postdoctoral trainings respectively at Oxford Brookes University (with Pr Linda King and Robert Possee, UK), University of Oxford (with Pr R.aymond Dwek and Dr Nicole Zitzmann, UK), and INSERM (National Institute for Health and Medical Research; with Pr Fabien Zoulim), I have obtained a tenured position in 2005 at INSERM, then my Habilitation to direct research in 2008 from the University of Lyon (UCBL), and was finally promoted Director of Research in 2016. During all these years, I worked on numerous research projects related to drug discovery (on both Direct Acting (DAA) and Host-Targeting Agents (HTA)) in the viral hepatitis field.

I currently leads a team at the International Center for Research in Infectiology (CIRI –INSERM U1111, http://ciri.inserm.fr/; Lyon), on a program of research aiming at better understanding the interplay between HBV/HDV and liver innate immunity in order to contribute to the development of novel host-targeting agents, in particular immune-therapeutics.

I received the 2021 William Prusoff award from the International Society for Antiviral Research (ISAR).

I have authored/coauthored 110 PubMed-recorded articles/reviews, as well as numerous proceedings/book chapters & was/am inventor in 10 patents. I acts as reviewers for many journals, including Gastroenterology, Gut, Hepatology, J. Hepatol, PlosPathogen, antiviral journals, et caetera

Since 2014, I am senior Editor for the Antiviral Research journal, section viral hepatitis, and, associated to this function, have co-organized several international antiviral conferences. I was recently nominated to organize the 2022 edition of the International HBV meeting.

I contribute to the French coordination on viral hepatitis research at ANRS (French Agency for AIDS and Hepatitis Research), seat in the board of several ANRS “study section” and “concerted action” committees and routinely organize workshops/conferences at National level. I was member of the executive board of the French Association for Liver Studies (AFEF) between 2015-2018, and am an active member of the European Association for the Study of the Liver (EASL).

Scientific summary

I currently head a team of 12-15 people working on the understanding of the interplay between the 2 hepatotropic oncoviruses HBV and HDV and liver innate immunity in order to identify host-factors that could be targeted for antiviral and anticancerous therapeutic strategies. We work on the development of those host targeting agents (HTA) from early stage to preclinical devopment using relevant mouse models we contibuted to develop and characterise. Some HTA can have a combined antiviral and anticancerous properties this defining what we call HTAC.

Our ultimate goal is to team-up with industrial partners or spin-off an activity to move forward an HTA or an HTAC to the clinic and improved upon current therapies against chronic viral hepatitis and related liver diseases.

Setected recent (2015-20) publications:

1. Chabrolles H, Auclair H, Vegna S, Lahlali T, Pons C, Michelet M, Couté Y, Belmudes L, Chadeuf G, Kim Y, Di Bernardo A, Jalaguier P, Cosset FL, Fusil F, Rivoire M, Arnold LD, Lopatin U, Combet C, Zoulim F, Grierson D, Chabot B, Lucifora J, Durantel D*, Salvetti A*. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. PLoS Pathog. 2020 Nov 12;16(11):e1008593. *Co-correspondance.

2. Lucifora J, Michelet M, Rivoire M, Protzer U, Durantel D*, Zoulim F*. Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work! J Hepatol. 2020 Aug;73(2):449-451. *Equal contribution.

3. Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebossé F, Fresquet J, Parent R,Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, KlumppK, Lam A, Zoulim F, Heikenwälder M, Durantel D*, Lucifora J*. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol. 2019, 71:1086-1098 (2019). *Co-last/co-corresponding author.

4. T. Lahlali, J. M. Berke, K. Vergauwen, A. Foca, K. Vandyck, F. Pauwels, F. Zoulim, D. Durantel. Novel potent capsid assembly modulators regulate multiple steps of the Hepatitis B virus life-cycle. Antimicrobial Agents and Chemotherapy 2018, 62(10):e00835-18.

5. J. Lucifora, M. Bonnin, L. Aillot, F. Fusil, S. Maadadi, L. Dimier, M. Michelet, O. Floriot, A. Ollivier, M. Rivoire, M. Ait-Goughoulte, S. Daffis, S. P. Fletcher, A. Salvetti, F. L. Cosset, F. Zoulim, D. Durantel. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Scientific reports 2018, 8(1):5390. 

6. L. Aillot, M. Bonnin, M. Ait-Goughoulte, N. Bendriss-Vermare, S. Maadadi, L. Dimier, M. Subic, C. Scholtes, I. Najera, F. Zoulim, J. Lucifora, D. Durantel. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrobial Agents and Chemotherapy  2018, 62(4):e01741-17. . 

7. J. Lucifora, A. Salvetti, X. Marniquet, L. Mailly, B. Testoni, F. Fusil, A. Inchauspe, M. Michelet, M. L. Michel, M. Levrero, P. Cortez, T. F. Baumert, F. L. Cosset, C. Challier, F. Zoulim, D. Durantel. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Research 2017, 145, 14-19. 

8. A. Diab, A. Foca, F. Fusil, T. Lahlali, P. Jalaguier, F. Amirache, L. N'Guyen, N. Isorce, F. L. Cosset, F. Zoulim, O. Andrisani, D. Durantel. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology 2017, 66, 1750-1765. 

9. D. Alfaiate, J. Lucifora, N. Abeywickrama-Samarakoon, M. Michelet, B. Testoni, J. C. Cortay, C. Sureau, F. Zoulim, P. Deny, D. Durantel. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Antiviral Research 2016, 136, 19-31. 

10. N. Isorce, B. Testoni, M. Locatelli, J. Fresquet, M. Rivoire, S. Luangsay, F. Zoulim, D. Durantel. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Research 2016, 130, 36-45.

11. S. Luangsay, M. Gruffaz, N. Isorce, B. Testoni, M. Michelet, S. Faure-Dupuy, S. Maadadi, M. Ait-Goughoulte, R. Parent, M. Rivoire, H. Javanbakht, J. Lucifora, D. Durantel*, F. Zoulim*. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015, 63, 1314-1322. *Co-last/co-corresponding author.

12. S. Luangsay, M. Ait-Goughoulte, M. Michelet, O. Floriot, M. Bonnin, M. Gruffaz, M. Rivoire, S. Fletcher, H. Javanbakht, J. Lucifora, F. Zoulim*, D. Durantel*. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. J Hepatol. 2015, 63, 1077-1085. *Co-last/co-corresponding author.

Image d’exemple